Arbutus Biopharma Corporation Common Stock
ABUSArbutus Biopharma Corporation is a biopharmaceutical company focused on developing therapies for viral diseases, particularly hepatitis B virus (HBV). The company leverages its proprietary delivery technologies to create targeted treatments aimed at curing chronic HBV infections. Established with a focus on innovative antiviral solutions, Arbutus Biopharma aims to address unmet medical needs in infectious diseases.
Company News
Moderna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 ...
Moderna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aim...
Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
